The global Neuroendocrine Carcinoma market was valued at US$ 1168 million in 2023 and is anticipated to reach US$ 1696 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.

Neuroendocrine Carcinoma Market

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

With the continuous advancement of medical technology, more accurate and faster diagnostic methods may be available for the detection of neuroendocrine cancer in the future. This may include more advanced imaging techniques, biomarker testing, and more that can help detect disease earlier and develop treatment options.

This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma.

Report Scope

The Neuroendocrine Carcinoma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuroendocrine Carcinoma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuroendocrine Carcinoma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neuroendocrine Carcinoma Market Report

Report Metric	Details
Report Name	Neuroendocrine Carcinoma Market
Accounted market size in 2023	US$ 1168 million
Forecasted market size in 2030	US$ 1696 million
CAGR	5.5%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Chemotherapy Somatostatin Analogs Targeted Therapy
Segment by Application	Hospital Clinics Oncology Centres Ambulatory Surgery Centres
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Novartis, Chiasma, Ipsen, Abbvie, Valeant, Jubilant, Teva, F.Hoffmann-La Roche, Advanced Accelerator, Mateon, Lexicon
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Carcinoma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neuroendocrine Carcinoma Market growing?

Ans: The Neuroendocrine Carcinoma Market witnessing a CAGR of 5.5% during the forecast period 2024-2030.

What is the Neuroendocrine Carcinoma Market size in 2030?

Ans: The Neuroendocrine Carcinoma Market size in 2030 will be US$ 1696 million.

Who are the main players in the Neuroendocrine Carcinoma Market report?

Ans: The main players in the Neuroendocrine Carcinoma Market are Pfizer, Novartis, Chiasma, Ipsen, Abbvie, Valeant, Jubilant, Teva, F.Hoffmann-La Roche, Advanced Accelerator, Mateon, Lexicon

What are the Application segmentation covered in the Neuroendocrine Carcinoma Market report?

Ans: The Applications covered in the Neuroendocrine Carcinoma Market report are Hospital, Clinics, Oncology Centres, Ambulatory Surgery Centres

What are the Type segmentation covered in the Neuroendocrine Carcinoma Market report?

Ans: The Types covered in the Neuroendocrine Carcinoma Market report are Chemotherapy, Somatostatin Analogs, Targeted Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Chemotherapy

1.2.3 Somatostatin Analogs

1.2.4 Targeted Therapy

1.3 Market by Application

1.3.1 Global Neuroendocrine Carcinoma Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinics

1.3.4 Oncology Centres

1.3.5 Ambulatory Surgery Centres

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuroendocrine Carcinoma Market Perspective (2019-2030)

2.2 Neuroendocrine Carcinoma Growth Trends by Region

2.2.1 Global Neuroendocrine Carcinoma Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Neuroendocrine Carcinoma Historic Market Size by Region (2019-2024)

2.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Region (2025-2030)

2.3 Neuroendocrine Carcinoma Market Dynamics

2.3.1 Neuroendocrine Carcinoma Industry Trends

2.3.2 Neuroendocrine Carcinoma Market Drivers

2.3.3 Neuroendocrine Carcinoma Market Challenges

2.3.4 Neuroendocrine Carcinoma Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neuroendocrine Carcinoma Players by Revenue

3.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2019-2024)

3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2019-2024)

3.2 Global Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Revenue

3.4 Global Neuroendocrine Carcinoma Market Concentration Ratio

3.4.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Revenue in 2023

3.5 Neuroendocrine Carcinoma Key Players Head office and Area Served

3.6 Key Players Neuroendocrine Carcinoma Product Solution and Service

3.7 Date of Enter into Neuroendocrine Carcinoma Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Neuroendocrine Carcinoma Breakdown Data by Type

4.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2019-2024)

4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2025-2030)

5 Neuroendocrine Carcinoma Breakdown Data by Application

5.1 Global Neuroendocrine Carcinoma Historic Market Size by Application (2019-2024)

5.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Neuroendocrine Carcinoma Market Size (2019-2030)

6.2 North America Neuroendocrine Carcinoma Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Neuroendocrine Carcinoma Market Size by Country (2019-2024)

6.4 North America Neuroendocrine Carcinoma Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neuroendocrine Carcinoma Market Size (2019-2030)

7.2 Europe Neuroendocrine Carcinoma Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Neuroendocrine Carcinoma Market Size by Country (2019-2024)

7.4 Europe Neuroendocrine Carcinoma Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neuroendocrine Carcinoma Market Size (2019-2030)

8.2 Asia-Pacific Neuroendocrine Carcinoma Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2019-2024)

8.4 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neuroendocrine Carcinoma Market Size (2019-2030)

9.2 Latin America Neuroendocrine Carcinoma Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Neuroendocrine Carcinoma Market Size by Country (2019-2024)

9.4 Latin America Neuroendocrine Carcinoma Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neuroendocrine Carcinoma Market Size (2019-2030)

10.2 Middle East & Africa Neuroendocrine Carcinoma Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2019-2024)

10.4 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuroendocrine Carcinoma Introduction

11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Neuroendocrine Carcinoma Introduction

11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.2.5 Novartis Recent Development

11.3 Chiasma

11.3.1 Chiasma Company Detail

11.3.2 Chiasma Business Overview

11.3.3 Chiasma Neuroendocrine Carcinoma Introduction

11.3.4 Chiasma Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.3.5 Chiasma Recent Development

11.4 Ipsen

11.4.1 Ipsen Company Detail

11.4.2 Ipsen Business Overview

11.4.3 Ipsen Neuroendocrine Carcinoma Introduction

11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.4.5 Ipsen Recent Development

11.5 Abbvie

11.5.1 Abbvie Company Detail

11.5.2 Abbvie Business Overview

11.5.3 Abbvie Neuroendocrine Carcinoma Introduction

11.5.4 Abbvie Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.5.5 Abbvie Recent Development

11.6 Valeant

11.6.1 Valeant Company Detail

11.6.2 Valeant Business Overview

11.6.3 Valeant Neuroendocrine Carcinoma Introduction

11.6.4 Valeant Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.6.5 Valeant Recent Development

11.7 Jubilant

11.7.1 Jubilant Company Detail

11.7.2 Jubilant Business Overview

11.7.3 Jubilant Neuroendocrine Carcinoma Introduction

11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.7.5 Jubilant Recent Development

11.8 Teva

11.8.1 Teva Company Detail

11.8.2 Teva Business Overview

11.8.3 Teva Neuroendocrine Carcinoma Introduction

11.8.4 Teva Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.8.5 Teva Recent Development

11.9 F.Hoffmann-La Roche

11.9.1 F.Hoffmann-La Roche Company Detail

11.9.2 F.Hoffmann-La Roche Business Overview

11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Introduction

11.9.4 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.9.5 F.Hoffmann-La Roche Recent Development

11.10 Advanced Accelerator

11.10.1 Advanced Accelerator Company Detail

11.10.2 Advanced Accelerator Business Overview

11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Introduction

11.10.4 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.10.5 Advanced Accelerator Recent Development

11.11 Mateon

11.11.1 Mateon Company Detail

11.11.2 Mateon Business Overview

11.11.3 Mateon Neuroendocrine Carcinoma Introduction

11.11.4 Mateon Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.11.5 Mateon Recent Development

11.12 Lexicon

11.12.1 Lexicon Company Detail

11.12.2 Lexicon Business Overview

11.12.3 Lexicon Neuroendocrine Carcinoma Introduction

11.12.4 Lexicon Revenue in Neuroendocrine Carcinoma Business (2019-2024)

11.12.5 Lexicon Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Somatostatin Analogs

Table 4. Key Players of Targeted Therapy

Table 5. Global Neuroendocrine Carcinoma Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Neuroendocrine Carcinoma Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Neuroendocrine Carcinoma Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Neuroendocrine Carcinoma Market Share by Region (2019-2024)

Table 9. Global Neuroendocrine Carcinoma Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Neuroendocrine Carcinoma Market Share by Region (2025-2030)

Table 11. Neuroendocrine Carcinoma Market Trends

Table 12. Neuroendocrine Carcinoma Market Drivers

Table 13. Neuroendocrine Carcinoma Market Challenges

Table 14. Neuroendocrine Carcinoma Market Restraints

Table 15. Global Neuroendocrine Carcinoma Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Neuroendocrine Carcinoma Market Share by Players (2019-2024)

Table 17. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2023)

Table 18. Ranking of Global Top Neuroendocrine Carcinoma Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Neuroendocrine Carcinoma Product Solution and Service

Table 22. Date of Enter into Neuroendocrine Carcinoma Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Neuroendocrine Carcinoma Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2019-2024)

Table 26. Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2025-2030)

Table 28. Global Neuroendocrine Carcinoma Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2019-2024)

Table 30. Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2025-2030)

Table 32. North America Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Neuroendocrine Carcinoma Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Neuroendocrine Carcinoma Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Neuroendocrine Carcinoma Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Neuroendocrine Carcinoma Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Neuroendocrine Carcinoma Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Neuroendocrine Carcinoma Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Neuroendocrine Carcinoma Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2025-2030) & (US$ Million)

Table 47. Pfizer Company Detail

Table 48. Pfizer Business Overview

Table 49. Pfizer Neuroendocrine Carcinoma Product

Table 50. Pfizer Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Novartis Company Detail

Table 53. Novartis Business Overview

Table 54. Novartis Neuroendocrine Carcinoma Product

Table 55. Novartis Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 56. Novartis Recent Development

Table 57. Chiasma Company Detail

Table 58. Chiasma Business Overview

Table 59. Chiasma Neuroendocrine Carcinoma Product

Table 60. Chiasma Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 61. Chiasma Recent Development

Table 62. Ipsen Company Detail

Table 63. Ipsen Business Overview

Table 64. Ipsen Neuroendocrine Carcinoma Product

Table 65. Ipsen Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 66. Ipsen Recent Development

Table 67. Abbvie Company Detail

Table 68. Abbvie Business Overview

Table 69. Abbvie Neuroendocrine Carcinoma Product

Table 70. Abbvie Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 71. Abbvie Recent Development

Table 72. Valeant Company Detail

Table 73. Valeant Business Overview

Table 74. Valeant Neuroendocrine Carcinoma Product

Table 75. Valeant Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 76. Valeant Recent Development

Table 77. Jubilant Company Detail

Table 78. Jubilant Business Overview

Table 79. Jubilant Neuroendocrine Carcinoma Product

Table 80. Jubilant Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 81. Jubilant Recent Development

Table 82. Teva Company Detail

Table 83. Teva Business Overview

Table 84. Teva Neuroendocrine Carcinoma Product

Table 85. Teva Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 86. Teva Recent Development

Table 87. F.Hoffmann-La Roche Company Detail

Table 88. F.Hoffmann-La Roche Business Overview

Table 89. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product

Table 90. F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 91. F.Hoffmann-La Roche Recent Development

Table 92. Advanced Accelerator Company Detail

Table 93. Advanced Accelerator Business Overview

Table 94. Advanced Accelerator Neuroendocrine Carcinoma Product

Table 95. Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 96. Advanced Accelerator Recent Development

Table 97. Mateon Company Detail

Table 98. Mateon Business Overview

Table 99. Mateon Neuroendocrine Carcinoma Product

Table 100. Mateon Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 101. Mateon Recent Development

Table 102. Lexicon Company Detail

Table 103. Lexicon Business Overview

Table 104. Lexicon Neuroendocrine Carcinoma Product

Table 105. Lexicon Revenue in Neuroendocrine Carcinoma Business (2019-2024) & (US$ Million)

Table 106. Lexicon Recent Development

Table 107. Research Programs/Design for This Report

Table 108. Key Data Information from Secondary Sources

Table 109. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neuroendocrine Carcinoma Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Neuroendocrine Carcinoma Market Share by Type: 2023 VS 2030

Figure 3. Chemotherapy Features

Figure 4. Somatostatin Analogs Features

Figure 5. Targeted Therapy Features

Figure 6. Global Neuroendocrine Carcinoma Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Neuroendocrine Carcinoma Market Share by Application: 2023 VS 2030

Figure 8. Hospital Case Studies

Figure 9. Clinics Case Studies

Figure 10. Oncology Centres Case Studies

Figure 11. Ambulatory Surgery Centres Case Studies

Figure 12. Neuroendocrine Carcinoma Report Years Considered

Figure 13. Global Neuroendocrine Carcinoma Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Neuroendocrine Carcinoma Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Neuroendocrine Carcinoma Market Share by Region: 2023 VS 2030

Figure 16. Global Neuroendocrine Carcinoma Market Share by Players in 2023

Figure 17. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Revenue in 2023

Figure 19. North America Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Neuroendocrine Carcinoma Market Share by Country (2019-2030)

Figure 21. United States Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Neuroendocrine Carcinoma Market Share by Country (2019-2030)

Figure 25. Germany Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Neuroendocrine Carcinoma Market Share by Region (2019-2030)

Figure 33. China Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Neuroendocrine Carcinoma Market Share by Country (2019-2030)

Figure 41. Mexico Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Neuroendocrine Carcinoma Market Share by Country (2019-2030)

Figure 45. Turkey Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia Neuroendocrine Carcinoma Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 48. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 49. Chiasma Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 50. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 51. Abbvie Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 52. Valeant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 53. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 54. Teva Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 55. F.Hoffmann-La Roche Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 56. Advanced Accelerator Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 57. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 58. Lexicon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2019-2024)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Colon Cancer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-31C5944

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10J13802

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Color Detection Sensors Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-6G9623

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Appendix Cancer Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2H1312

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions